{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:48:38Z","timestamp":1792039718497,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258384"],"award-info":[{"award-number":["R01CA258384"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U19CA264504"],"award-info":[{"award-number":["U19CA264504"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012394","name":"Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010612","name":"ChadTough Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR250137"],"award-info":[{"award-number":["RR250137"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antiseizure medications, such as levetiracetam, are commonly used in glioma patients. Retrospective analyses evaluating effects of antiseizure medications on glioma patient survival have yielded inconsistent results, probably due to confounding factors of glioma subtype and drug class. Here we present retrospective real-world clinical data that demonstrate longer overall survival for children with diffuse midline glioma (DMG) who were taking levetiracetam, which was not evident in pediatric patients with hemispheric high-grade glioma. In preclinical models, levetiracetam reduces glioma proliferation and tumor burden, extending survival of mice bearing DMG orthotopic xenografts. These beneficial effects were not found in hemispheric high-grade glioma patient-derived orthotopic xenograft models. The subtype-specificity of this antiproliferative effect of levetiracetam is congruent with recent findings that GABAergic neuron-to-glioma synapses promote glioma growth in DMG but not hemispheric high-grade glioma. We demonstrate here that levetiracetam attenuates low-frequency GABAergic synaptic transmission in a glioma-specific manner, reducing GABAergic synaptic currents in DMG but not in healthy neurons. This effect is independent of action on SV2A, the chief mechanism by which levetiracetam functions to prevent and treat seizures. Taken together, these findings indicate a promising approach to target GABAergic synapses in DMG and suggest that use of levetiracetam in DMG should be further studied in future prospective clinical studies.<\/jats:p>","DOI":"10.1038\/s41591-026-04646-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:33Z","timestamp":1789635753000},"page":"3792-3800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma"],"prefix":"10.1038","volume":"32","author":[{"given":"Tara","family":"Barron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Drexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1073-916X","authenticated-orcid":false,"given":"Aaron","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-705X","authenticated-orcid":false,"given":"Kiarash","family":"Shamardani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamelyn J.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4191-6723","authenticated-orcid":false,"given":"Neeraj","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Tlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7683","authenticated-orcid":false,"given":"Andrea","family":"Franson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-188X","authenticated-orcid":false,"given":"Samantha","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9501-823X","authenticated-orcid":false,"given":"Truman","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Raber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-5204","authenticated-orcid":false,"given":"Michael A.","family":"Quezada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Keough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0200-1310","authenticated-orcid":false,"given":"Samin Malaki","family":"Jahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Thuy","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Herrera","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5827-7152","authenticated-orcid":false,"given":"Kim","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-6930","authenticated-orcid":false,"given":"Franz L.","family":"Ricklefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-1121","authenticated-orcid":false,"given":"Ulrich","family":"Sch\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-9357","authenticated-orcid":false,"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-1590","authenticated-orcid":false,"given":"Paul G.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3519-1375","authenticated-orcid":false,"given":"Cynthia J.","family":"Campen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-7689","authenticated-orcid":false,"given":"Sonia","family":"Partap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0668-5955","authenticated-orcid":false,"given":"Kai","family":"Kaila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-237X","authenticated-orcid":false,"given":"Michelle","family":"Monje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"4646_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 https:\/\/doi.org\/10.1093\/neuonc\/noab106 (2021).","journal-title":"Neuro Oncol."},{"key":"4646_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cell.2015.04.012","volume":"161","author":"HS Venkatesh","year":"2015","unstructured":"Venkatesh, H. S. et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell 161, 803\u2013816 https:\/\/doi.org\/10.1016\/j.cell.2015.04.012 (2015).","journal-title":"Cell"},{"key":"4646_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nature24014","volume":"549","author":"HS Venkatesh","year":"2017","unstructured":"Venkatesh, H. S. et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549, 533\u2013537 https:\/\/doi.org\/10.1038\/nature24014 (2017).","journal-title":"Nature"},{"key":"4646_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03580-6","volume":"594","author":"Y Pan","year":"2021","unstructured":"Pan, Y. et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature 594, 277\u2013282 https:\/\/doi.org\/10.1038\/s41586-021-03580-6 (2021).","journal-title":"Nature"},{"key":"4646_CR5","doi-asserted-by":"publisher","unstructured":"Chen, P. et al. Olfactory sensory experience regulates gliomagenesis via neuronal IGF1. Nature 606, 550\u2013556 https:\/\/doi.org\/10.1038\/s41586-022-04719-9 (2022).","DOI":"10.1038\/s41586-022-04719-9"},{"key":"4646_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","volume":"623","author":"KR Taylor","year":"2023","unstructured":"Taylor, K. R. et al. Glioma synapses recruit mechanisms of adaptive plasticity. Nature 623, 366\u2013374 https:\/\/doi.org\/10.1038\/s41586-023-06678-1 (2023).","journal-title":"Nature"},{"key":"4646_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41586-023-06267-2","volume":"619","author":"E Huang-Hobbs","year":"2023","unstructured":"Huang-Hobbs, E. et al. Remote neuronal activity drives glioma progression through SEMA4F. Nature 619, 844\u2013850 https:\/\/doi.org\/10.1038\/s41586-023-06267-2 (2023).","journal-title":"Nature"},{"key":"4646_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","volume":"573","author":"HS Venkatesh","year":"2019","unstructured":"Venkatesh, H. S. et al. Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539\u2013545 https:\/\/doi.org\/10.1038\/s41586-019-1563-y (2019).","journal-title":"Nature"},{"key":"4646_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532\u2013538 https:\/\/doi.org\/10.1038\/s41586-019-1564-x (2019).","journal-title":"Nature"},{"key":"4646_CR10","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","volume":"185","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185, 2899\u20132917 https:\/\/doi.org\/10.1016\/j.cell.2022.06.054 (2022).","journal-title":"Cell"},{"key":"4646_CR11","doi-asserted-by":"publisher","unstructured":"Barron, T. et al. GABAergic neuron-to-glioma synapses in diffuse midline gliomas. Nature 639, 1060\u20131068 https:\/\/doi.org\/10.1038\/s41586-024-08579-3 (2025).","DOI":"10.1038\/s41586-024-08579-3"},{"key":"4646_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm.2453","volume":"17","author":"SC Buckingham","year":"2011","unstructured":"Buckingham, S. C. et al. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med. 17, 1269\u20131274 https:\/\/doi.org\/10.1038\/nm.2453 (2011).","journal-title":"Nat. Med."},{"key":"4646_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1528-1167.2012.03557.x","volume":"53","author":"SL Campbell","year":"2012","unstructured":"Campbell, S. L., Buckingham, S. C. & Sontheimer, H. Human glioma cells induce hyperexcitability in cortical networks. Epilepsia 53, 1360\u20131370 https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03557.x (2012).","journal-title":"Epilepsia"},{"key":"4646_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nn.4493","volume":"20","author":"CC John Lin","year":"2017","unstructured":"John Lin, C. C. et al. Identification of diverse astrocyte populations and their malignant analogs. Nat. Neurosci. 20, 396\u2013405 https:\/\/doi.org\/10.1038\/nn.4493 (2017).","journal-title":"Nat. Neurosci."},{"key":"4646_CR15","doi-asserted-by":"publisher","unstructured":"Yu, K. et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature 578, 166\u2013171 https:\/\/doi.org\/10.1038\/s41586-020-1952-2 (2020).","DOI":"10.1038\/s41586-020-1952-2"},{"key":"4646_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","volume":"617","author":"S Krishna","year":"2023","unstructured":"Krishna, S. et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature 617, 599\u2013607 https:\/\/doi.org\/10.1038\/s41586-023-06036-1 (2023).","journal-title":"Nature"},{"key":"4646_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","volume":"23","author":"T Walbert","year":"2021","unstructured":"Walbert, T. et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 23, 1835\u20131844 https:\/\/doi.org\/10.1093\/neuonc\/noab152 (2021).","journal-title":"Neuro Oncol."},{"key":"4646_CR18","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1212\/WNL.0000000000013005","volume":"98","author":"J Pallud","year":"2022","unstructured":"Pallud, J. et al. Effect of levetiracetam use duration on overall survival of isocitrate dehydrogenase wild-type glioblastoma in adults: an observational study. Neurology 98, e125\u2013e140 https:\/\/doi.org\/10.1212\/WNL.0000000000013005 (2022).","journal-title":"Neurology"},{"key":"4646_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","volume":"34","author":"C Happold","year":"2016","unstructured":"Happold, C. et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J. Clin. Oncol. 34, 731\u2013739 https:\/\/doi.org\/10.1200\/JCO.2015.63.6563 (2016).","journal-title":"J. Clin. Oncol."},{"key":"4646_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-021-03940-2","volume":"156","author":"JS Chen","year":"2022","unstructured":"Chen, J. S. et al. The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis. J. Neurooncol. 156, 257\u2013267 https:\/\/doi.org\/10.1007\/s11060-021-03940-2 (2022).","journal-title":"J. Neurooncol."},{"key":"4646_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11060-014-1448-8","volume":"119","author":"NJ Robison","year":"2014","unstructured":"Robison, N. J. & Kieran, M. W. Diffuse intrinsic pontine glioma: a reassessment. J. Neurooncol. 119, 7\u201315 https:\/\/doi.org\/10.1007\/s11060-014-1448-8 (2014).","journal-title":"J. Neurooncol."},{"key":"4646_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay, A. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32, 520\u2013537 https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017 (2017).","journal-title":"Cancer Cell"},{"key":"4646_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 19, 1279\u20131280 https:\/\/doi.org\/10.1093\/neuonc\/nox107 (2017).","journal-title":"Neuro Oncol."},{"key":"4646_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2019.08.013","volume":"179","author":"GB Kim","year":"2019","unstructured":"Kim, G. B. et al. Rapid generation of somatic mouse mosaics with locus-specific, stably integrated transgenic elements. Cell 179, 251\u2013267 https:\/\/doi.org\/10.1016\/j.cell.2019.08.013 (2019).","journal-title":"Cell"},{"key":"4646_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrn3819","volume":"15","author":"K Kaila","year":"2014","unstructured":"Kaila, K., Price, T. J., Payne, J. A., Puskarjov, M. & Voipio, J. Cation-chloride cotransporters in neuronal development, plasticity and disease. Nat. Rev. Neurosci. 15, 637\u2013654 https:\/\/doi.org\/10.1038\/nrn3819 (2014).","journal-title":"Nat. Rev. Neurosci."},{"key":"4646_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/s0028-3908(01)00185-x","volume":"42","author":"P Poulain","year":"2002","unstructured":"Poulain, P. & Margineanu, D. G. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 42, 346\u2013352 https:\/\/doi.org\/10.1016\/s0028-3908(01)00185-x (2002).","journal-title":"Neuropharmacology"},{"key":"4646_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","volume":"136","author":"JM Rigo","year":"2002","unstructured":"Rigo, J. M. et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br. J. Pharmacol. 136, 659\u2013672 https:\/\/doi.org\/10.1038\/sj.bjp.0704766 (2002).","journal-title":"Br. J. Pharmacol."},{"key":"4646_CR28","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch, B. A. et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA 101, 9861\u20139866 https:\/\/doi.org\/10.1073\/pnas.0308208101 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4646_CR29","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/j.1528-1167.2006.01132.x","volume":"48","author":"XF Yang","year":"2007","unstructured":"Yang, X. F., Weisenfeld, A. & Rothman, S. M. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 48, 1861\u20131869 https:\/\/doi.org\/10.1111\/j.1528-1167.2006.01132.x (2007).","journal-title":"Epilepsia"},{"key":"4646_CR30","doi-asserted-by":"publisher","first-page":"e29560","DOI":"10.1371\/journal.pone.0029560","volume":"6","author":"A Nowack","year":"2011","unstructured":"Nowack, A. et al. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS ONE 6, e29560 https:\/\/doi.org\/10.1371\/journal.pone.0029560 (2011).","journal-title":"PLoS ONE"},{"key":"4646_CR31","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/epi.13223","volume":"56","author":"X Yang","year":"2015","unstructured":"Yang, X. et al. Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia 56, 1899\u20131909 https:\/\/doi.org\/10.1111\/epi.13223 (2015).","journal-title":"Epilepsia"},{"key":"4646_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1528-1167.2011.03392.x","volume":"53","author":"AL Meehan","year":"2012","unstructured":"Meehan, A. L., Yang, X., Yuan, L. L. & Rothman, S. M. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 53, 469\u2013476 https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03392.x (2012).","journal-title":"Epilepsia"},{"key":"4646_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/pl00005097","volume":"356","author":"S Birnstiel","year":"1997","unstructured":"Birnstiel, S., Wulfert, E. & Beck, S. G. Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch. Pharmacol. 356, 611\u2013618 https:\/\/doi.org\/10.1007\/pl00005097 (1997).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"4646_CR34","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1016\/j.cell.2025.05.031","volume":"188","author":"R Drexler","year":"2025","unstructured":"Drexler, R. et al. Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling. Cell 188, 4640\u20134657.e30 (2025).","journal-title":"Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04646-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04646-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:32:01Z","timestamp":1792038721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04646-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4646"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04646-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. holds equity in MapLight Therapeutics and Stellaromics and is on the SAB of S1 Oncology. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}